Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Titel:
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Auteur:
Reich, Kristian Papp, Kim A Blauvelt, Andrew Langley, Richard G Armstrong, April Warren, Richard B Gordon, Kenneth B Merola, Joseph F Okubo, Yukari Madden, Cynthia Wang, Maggie Cioffi, Christopher Vanvoorden, Veerle Lebwohl, Mark